New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTPFE, PFE, SHPG, SHPG, AZN, AZN, BMY, BMY, TEVA, TEVA, INCY, INCY, RHHBY, RHHBYCBI to host a conference
12th Annual Bio/Pharmaceutical Contact Centers Conference is being held in Philadelphia on January 23-24.
News For PFE;SHPG;AZN;BMY;TEVA;INCY;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
08:08 EDTPFEPfizer director Marc Tessier-Lavigne to step down from board
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
05:52 EDTAZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
19:17 EDTPFEHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
17:19 EDTPFEPfizer, Merck KGaA to present data at ASCO for avelumab
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
13:43 EDTPFEHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information
07:31 EDTPFEHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
07:52 EDTSHPGLeerink to hold a tour
Subscribe for More Information
May 11, 2015
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
14:27 EDTTEVACowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
11:53 EDTTEVATeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
05:11 EDTRHHBYRoche receives FDA approval for cobas KRAS Mutation Test
Roche announced that the FDA has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer, or mCRC, patients and aid clinicians in determining a therapeutic path for them.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use